Medicine
Desferal 500 mg powder for injection
Desferal 500 mg powder for injection is a prescription medicine containing Deferoxamine for intramuscular, intravenous, subcutaneous use, marketed by Novartis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and…
Key facts
- Active ingredient (INN)
- Deferoxamine
- Brand
- Desferal
- Strength
- 500 mg
- Dosage form
- Powder for injection
- Route
- Intramuscular, intravenous, subcutaneous
- Packs
- 4 vials
- Marketing authorisation holder
- Novartis Pharmaceuticals
- Manufacturer
- Novartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V03AC01 Deferoxamine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 April 1968
- Identifiers
- RxCUI 1731350, 1731352DailyMed set ID a7174843-5965-49fc-b842-f7eff7b48bbcNDC 0078-0467Application NDA016267
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 vial in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial | 0078-0467-91 | Novartis Pharmaceuticals | 2 April 1968 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 1 April 1968 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Deferoxamine 500 mg powder for injection.
Other strengths and forms of Deferoxamine
Clinical summary
Deferoxamine is an iron chelator indicated as an adjunct to standard measures for the treatment of acute iron intoxication, among other approved uses. It is available as powder for injection for intravenous, intramuscular and subcutaneous use. MedsAcross supplies Deferoxamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DeferoxamineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Desferal prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Desferal 500 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.